Danaher Corporation vs RLX Technology Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: Danaher Corporation is far larger — about 72.8× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and RLX Technology Inc for 35 Days on average.
| DHR | RLX | |
|---|---|---|
Market Cap | $152.87B | $2.10B |
Volume | 5,228,698 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $242.05 | $2.57 |
52-Week Low | $161.91 | $1.68 |
Typical Hold Time | 69 Days | 35 Days |
Enterprise Value | $175.08B | $832.26M |
Dividend Yield | 0.74% | 5.81% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
RLX Technology trades at $1.72, down 0.58% and near its 52-week low, with a bearish technical signal from moving averages. Fundamentally, the company shows solid profitability with 21.87% net income margin and attractive valuation metrics including P/E of 15.46 and P/B of 0.91. Recent quarterly earnings have consistently missed expectations, though revenue growth remains positive with 2026 projections showing $4.5B revenue and $985M net income.
The stock presents a value opportunity given discounted valuation, but faces headwinds from earnings misses and bearish technicals. International expansion through European acquisitions provides growth catalysts, though execution risks and margin compression require monitoring. Analyst sentiment remains cautious with 100% hold rating, suggesting limited near-term upside potential despite fundamental strengths.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →